{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:29:34Z","timestamp":1790792974057,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jcrs.2012.10.039","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T22:31:12Z","timestamp":1355005872000},"page":"168-173","source":"Crossref","is-referenced-by-count":43,"title":["Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery"],"prefix":"10.1097","volume":"39","author":[{"given":"Stephen S.","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2007.132621","article-title":"Treatment of ocular inflammatory conditions with loteprednol etabonate.","volume":"92","author":"Pavesio","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R2-4-20210210","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1023\/A:1015849132396","article-title":"Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.","volume":"9","author":"Bodor","year":"1992","journal-title":"Pharm Res"},{"key":"R3-4-20210210","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/02713689109020329","article-title":"Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.","volume":"10","author":"Druzgala","year":"1991","journal-title":"Curr Eye Res"},{"key":"R5-4-20210210","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.1993.9.157","article-title":"Intraocular pressure response to loteprednol etabonate in known steroid responders.","volume":"9","author":"Bartlett","year":"1993","journal-title":"J Ocul Pharmacol"},{"key":"R6-4-20210210","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00061198-199808000-00009","article-title":"Change in intraocular pressure during long-term use of loteprednol etabonate.","volume":"7","author":"Novack","year":"1998","journal-title":"J Glaucoma"},{"key":"R7-4-20210210","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(14)71128-6","article-title":"A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis; Loteprednol Allergic Conjunctivitis Study Group.","volume":"123","author":"Dell","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"R8-4-20210210","first-page":"31","article-title":"A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.","volume":"23","author":"Asbell","year":"1997","journal-title":"CLAO J"},{"key":"R9-4-20210210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0002-9394(14)70171-0","article-title":"A double-masked, placebo controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis; the Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.","volume":"123","author":"Friedlander","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"R10-4-20210210","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9394(99)00034-3","article-title":"Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis.","volume":"127","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R11-4-20210210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5, and placebo for the treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R12-4-20210210","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0886-3350(98)80170-3","article-title":"Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation; Loteprednol Etabonate Post-Operative Inflammation Study Group 1.","volume":"24","author":"Stewart","year":"1998","journal-title":"J Cataract Refract Surg"},{"key":"R13-4-20210210","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0161-6420(98)99054-6","article-title":"A double-masked, placebo-controlled evaluation of 0.5 loteprednol etabonate in the treatment of postoperative inflammation.","volume":"105","year":"1998","journal-title":"Ophthalmology"},{"key":"R15-4-20210210","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/ICO.0b013e31815873c7","article-title":"Effects of loteprednoltobramycin versus dexamethasonetobramycin on intraocular pressure in healthy volunteers.","volume":"27","author":"Holland","year":"2008","journal-title":"Cornea"},{"key":"R16-4-20210210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1185\/030079908X253898","article-title":"Comparison of the safety and efficacy of loteprednol 0.5tobramycin 0.3 with dexamethasone 0.1tobramycin 0.3 in the treatment of blepharokeratoconjunctivitis.","volume":"24","author":"White","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R17-4-20210210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcrs.2008.09.024","article-title":", Difluprednate Ophthalmic Emulsion 0.05 (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05 for postoperative inflammation and pain.","volume":"35","author":"Korenfeld","year":"2009","journal-title":"J Cataract Refract Surg"}],"container-title":["Journal of Cataract and Refractive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335012015386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335012015386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1016\/j.jcrs.2012.10.039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T17:06:25Z","timestamp":1620925585000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02158034-201302000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jcrs.2012.10.039","relation":{},"ISSN":["0886-3350"],"issn-type":[{"value":"0886-3350","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}